

LSZ-102

Catalog No: **tcsc0042193**



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

2135600-76-7

Formula:

$C_{25}H_{17}F_3O_4S$

Pathway:

Others

Target:

Estrogen Receptor/ERR

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

470.46

Product Description


LSZ-102 is a potent, orally bioavailable selective **estrogen receptor** degrader with an **IC₅₀** of 0.2 nM.

IC50 & Target: estrogen receptor^[1]

In Vitro:

LSZ-102 is a potent, orally bioavailable selective estrogen receptor degrader with an IC_{50} of 0.2 nM and currently in Phase I/II trials for the treatment of ER α positive breast cancer. LSZ-102 induces significant degradation of ER α after 24 h, when given as a 10 μ M solution to MCF-7 cells. Robust inhibition of cell proliferation in MCF-7 cells is observed upon incubation with LSZ-102 with a half inhibitory concentration of 1.7 nM. Results demonstrate that LSZ-102 effectively inhibits the estrogen-induced activation of the ERE-luciferase reporter using charcoal-stripped serum treated with E2 with IC_{50} of 0.3 nM^[1].

In Vivo: Treatment of the mice with LSZ-102 once daily at 20 mg/kg results in significant tumor growth inhibition as compared to the control group treated with vehicle alone, resulting in tumor stasis (mean change in tumor volume of LSZ-102 vs control = $\% \Delta T / \Delta C$ of 2.4% on day 48, p[1]).



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!